Home/Pipeline/MyCardia™

MyCardia™

Heart Failure

Pre-clinicalActive

Key Facts

Indication

Heart Failure

Phase

Pre-clinical

Status

Active

Company

Avery Therapeutics

About Avery Therapeutics

Avery Therapeutics is a private, pre-revenue biotech advancing a novel immunomodulatory platform for tissue regeneration, initially targeting heart failure with its lead candidate, MyCardia™. The company leverages strong scientific and medical advisory boards and is led by founder and CEO Jordan Lancaster, PhD. Operating in the high-value but challenging field of advanced tissue engineering, Avery aims to provide a restorative therapeutic option for a major unmet medical need in cardiovascular disease.

View full company profile

Therapeutic Areas

Cardiovascular Musculoskeletal

Other Heart Failure Drugs

Drug	Company	Phase	Status
Cardiac Cell Therapy Program	StemCardia	Pre-clinical	Active
NTP42	ATXA Therapeutics	Preclinical	Platform potential identified
Heart Failure Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
INPEFA (sotagliflozin)	Lexicon Pharmaceuticals	Approved	Commercial
Cardiac Assist Device	Second Heart Assist	Pre-clinical	Active
Isosorbide Dinitrate/Hydralazine HCl Tablets	i3 Pharmaceuticals	Approved	Active
TLT-101	TikkunLev Therapeutics	Pre-clinical	Active
Undisclosed Heart Regeneration Program	Animatus Biosciences	Pre-clinical	Active
AFteR Registry	Occlutech	N/A (Registry)	Active
biotx.ai Target Discovery Collaboration	HeartBeat.bio	Pre-clinical	Active
Surlorian	RyCarma Therapeutics	Phase 2	Active
Coronary Sinus Reduction	Shockwave Medical	Unknown	Active